Drug Approval | June 14, 2024
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
EDQM has also issued a Certificate of Suitability for Allopurino
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Subscribe To Our Newsletter & Stay Updated
